efavirenz and idx 899

efavirenz has been researched along with idx 899 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alexandre, FR; Amador, A; Bonaric, S; Bot, S; Caillet, C; Convard, T; da Costa, D; Dousson, C; Hubbard, L; Jakubik, J; Lioure, MP; Liuzzi, M; Maldonado, S; Mayes, BA; Moussa, A; Musiu, C; Parsy, C; Poddesu, B; Roland, A; Rosinovsky, E; Seifer, M; Standring, D; Stewart, A; Storer, R; Trochet, C; Vargiu, L; Wang, J	1
Dudas, K; Dumont, E; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; St Clair, M; White, S; Zala, C; Zhou, XJ	1

Trials

1 trial(s) available for efavirenz and idx 899

Article	Year
Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:5 Topics: Adult; Alkynes; Anti-HIV Agents; Argentina; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Male; Mutation; Phosphinic Acids; Placebos; Reverse Transcriptase Inhibitors; Viral Load	2012

Article

Year

Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:5

Topics: Adult; Alkynes; Anti-HIV Agents; Argentina; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Male; Mutation; Phosphinic Acids; Placebos; Reverse Transcriptase Inhibitors; Viral Load

2012

Other Studies

1 other study(ies) available for efavirenz and idx 899

Article	Year
Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor. Journal of medicinal chemistry, 2016, Mar-10, Volume: 59, Issue:5 Topics: Animals; Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Hepatocytes; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Macaca fascicularis; Male; Models, Molecular; Molecular Structure; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2016

Article

Year

Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.

Journal of medicinal chemistry, 2016, Mar-10, Volume: 59, Issue:5

Topics: Animals; Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Hepatocytes; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Macaca fascicularis; Male; Models, Molecular; Molecular Structure; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2016